Physicians' Academy for Cardiovascular Education

More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses

AHA 2017 - Anaheim, CA, USA

3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA

AHA 2017 Dr. Giugliano summarises findings of 2 additional clinical trial updates and studies into infarct size, TIMI stable IHD risk and total events in the FOURIER trial.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the AHA 2017 congress. The objective is to provide a brief commentary and potential implications of these findings.


- Our reporting is based on the information provided at the AHA 2017 congress -

Marc Sabatine: Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition Marc Bonaca: Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: